ASEM 文献综述
Official American Association of Clinical Endocrinology document (2022) on “2022 Consensus Statement on Immune Checkpoint Inhibitor-Mediated Endocrinopathies”. This consensus statement provides a practical approach for management of patients with immune checkpoint inhibitor (ICI)-mediated endocrinopathies with case scenarios of various clinical manifestations and highlights the role of the endocrinology team in the multidisciplinary management of ICI-induced endocrinopathies. The statement summarizes the use of ICI (anti-CTLA-4, anti-PD1, and anti-PD-L1) therapies; reviews.
此摘要有助于您识别文档。对于临床建议，请始终查阅官方现行版本及其更新日期。
官方文档